

Remarks

Claim 1 has been amended to correct an inadvertent error in the proviso in the last two lines of this claim concerning the definitions for m and n. Support for this change is found on page 4, lines 8-9 from the bottom of the specification.

The multiple dependent claims have been amended to depend from only a single preceding claim, in order to reduce the filing fee.

Claim 8 has been amended to insert the formulae at page 8, lines 1-3, which are missing from original claim 8.

Claim 9 has been amended to incorporate the definition of the C ring from claim 5, and the definition of R¹ from claim 7.

Claim 20 has been amended to insert a requirement for a pharmaceutically acceptable carrier or diluent (based on page 43, line 10 of the specification), in order to more clearly distinguish this claim from claim 1.

New claims 23-29 have been added to the application.

New claim 23 is the same as original claim 6 except that it is dependent on claim 9.

New claim 24 is the same as amended claim 8 except that it is dependent on claim 9.


New claims 25-28 are the same as original claims 13-16, respectively, except that they are dependent on claim 12.

New claim 29 is the same as original claim 19 except that it is dependent on claim 18.

The original Abstract begins on the same page (page 134) as some of the claims. To correct this, the original Abstract has been replaced by a new Abstract on a separate sheet attached hereto. The new Abstract has been shortened in an effort to keep it within PTO guidelines.

Respectfully submitted,

Hidenori MIKAMIYAMA et al.

By: 
Michael R. Davis
Registration No. 25,134
Attorney for Applicants

MRD/pth
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 21, 2006